Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrpmArpmBrpmCrpmDrpmE2rpmFrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsU
The experimentally established mechanism targets of Troleandomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.38 |
| ▸ | MLNR | O43193 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troleandomycin SCHEMBL125070 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNAPGR | |
| Troleandomycin SCHEMBL125071 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNAPGR | |
| Troleandomycin SCHEMBL29470683 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNAPGR | |
| Troleandomycin SCHEMBL28198745 | 0.97 | CYP3A4 (0.94) | CYP3A4USP2ABCB1LMNAPGR | |
| Troleandomycin SCHEMBL3065803 | 0.89 | CYP3A4 (0.79) | CYP3A4USP2ABCB1LMNAPGR | |
| SCHEMBL15944213 | 0.89 | CYP3A4 (0.80) | CYP3A4USP2ABCB1LMNAPGR | |
| Diproleandomycin SCHEMBL2109038 | 0.88 | CYP3A4 (0.78) | CYP3A4USP2ABCB1LMNAPGR | |
| SCHEMBL26436882 | 0.84 | CYP3A4 (0.72) | CYP3A4USP2ABCB1LMNAPGR | |
| Oleandomycin SCHEMBL3716 | 0.83 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNASLCO1B3 | |
| Oleandomycin SCHEMBL10028439 | 0.83 | CYP3A4 (1.00) | CYP3A4USP2ABCB1LMNASLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 796 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11110209-B2 | Intraluminal therapy system for gastrointestinal infections | MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITAL (TW) | 2021-09-07 | — | — | US | claimed |
| CN-109069471-A | Compositions and methods for treating influenza virus | 新兴病毒治疗（香港）公司 | 2018-12-21 | — | — | CN | claimed |
| US-20180221542-A1 | INTRALUMINAL THERAPY SYSTEM FOR GASTROINTESTINAL INFECTIONS | MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITAL (TW) | 2018-08-09 | — | — | US | claimed |
| WO-2018136598-A1 | METHODS OF TREATING CANCER | EVELO BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | claimed |
| WO-2018136617-A2 | METHODS OF TREATING CANCER | EVELO BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | claimed |
| US-20180002741-A1 | METHOD OF DIAGNOSIS AND TREATING GASTROINTESTINAL AND NEUROLOGICAL DISEASES ASSOCIATED WITH SPECIES OF GENUS CLOSTRIDIUM | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2018-01-04 | — | — | US | claimed |
| CN-106414487-A | Ligand binding molecules and uses thereof | 韦格尼奇有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-106414465-A | Charged linkers and their use in conjugation reactions | 杭州多禧生物科技有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-104232503-B | Bacillus shacheensis and application thereof | 四川大学 | 2017-01-25 | — | — | CN | claimed |
| CN-106063948-A | A kind of long-acting hypodermic implant and preparation method thereof | 圆容生物医药无锡有限公司 | 2016-11-02 | — | — | CN | claimed |
| US-20040062757-A1 | Method of testing gastrointestinal diseases associated with species of genus clostridium | THE UNITED STATES OF AMERICA AS REPRESENTED BY | 2004-04-01 | — | — | US | claimed |
| US-6669842-B1 | Crystallization, precipitation, filtration, electrophoresis, and chromatography using ansamacrolides, macrolides, macrocyclic peptides, or polyenes; resolution | CURATORS OF THE UNIVERSITY OF MISSOURI | 2003-12-30 | — | — | US | claimed |
| EP-1185274-A1 | DRUG COMBINATIONS COMPRISING (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND AN INHIBITOR, INDUCER OR SUBSTRATE OF P450 ISOENZYME 3A4 | AstraZeneca AB (SE) | 2002-03-13 | — | — | EP | claimed |
| CN-1338936-A | Pharmaceutical composition comprising an inhibitor, inducer or substrate of -7- [ 4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidin-5 yl ] (3R,5S) -3, 5-dihydroxyhept-6-enoic acid and P450 isozyme 3A4 | ASTRAZENECA AB (SE) | 2002-03-06 | — | — | CN | claimed |
| WO-2001097749-A2 | THE USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS AND THEREOF | KOTZE, GAVIN, SALOMON (ZA) | 2001-12-27 | — | — | WO | claimed |
| WO-2001093904-A1 | METHOD OF TREATING GASTROINTESTINAL DISEASES ASSOCIATED WITH SPECIES OF GENUS CLOSTRIDIUM | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2001-12-13 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2000045817-A1 | DRUG COMBINATIONS COMPRISING (E) -7 - [4 -(4 -FLUOROPHENYL) -6 - ISOPROPYL -2 - [METHYL (METHYLSULFONYL) AMINO] PYRIMIDIN -5 -YL] (3R,5S) -3,5 - DIHYDROXYHEPT -6 - ENOIC ACID AND AN INHIBITOR, INDUCER OR SUBSTRATE OF P450 ISOENZYME 3A4 | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | claimed |
| US-5964996-A | ELECTROPHORESIS OF FLUID CONTAINING THE ENANTIOMERS WITH A MACROCYCLIC ANTIBIOTIC, WHICH CAUSES SEQUENTIAL SEPARATION OF ENANTIOMERS BY COMPLEXATION, INCLUSION, HYDROGEN BONDING, DIPOLE STACKING OR STERIC INTERACTION | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1999-10-12 | — | — | US | claimed |
| US-5874005-A | SEPARATION OF ENANTIOMORPHS IN SOLUTION; CHROMATOGRAPHY, ELECTROPHORESIS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1999-02-23 | — | — | US | claimed |